Arnaud Méjean from the HEGP, Université Paris Descartes and ADHP in Paris, France, discusses the place of cytoreductive nephrectomy in the management of patients with metastatic renal cell carcinoma, and how this approach may change based on the results of the CARMENA trial.
1. What is the current role of cytoreductive nephrectomy in the management of patients with metastatic renal cell carcinoma? (0:11)
2. How did the advent of targeted therapies affect the use of cytoreductive nephrectomy? (0:32)
3. Could you tell us a little about the design of the CARMENA clinical trial? (0:58)
4. What were the findings of this study? (2:02)
5. What patients are most likely to benefit from this approach? (3:08)
Speaker disclosures: Arnaud Méjean has nothing to disclose in relation to this video interview.
Filmed at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018, Chicago, IL, US, June 1–5 2018